ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 40944871

Anlotinib in cancer therapy: mechanisms of action, clinical applications, and future perspectives.

Ding J and 7 others. Cancer Chemother Pharmacol, 2025. Cited by 3 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Anlotinib in cancer therapy: mechanisms of action, clinical applications, and future perspectives. Papers, record 40944871. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40944871

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anlotinib in cancer therapy: mechanisms of action, clinical applications, and future perspectives.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-06-26
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ding JJianhua
2Yeong CHChai Hong
3Wang LLei
4Shi CChunyan
5Li LLong
6Song LLijun
7Ma WWenxiu
8Li PPeng

Source PubMed

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
IndolesMajor topic
QuinolinesMajor topic
NeoplasmsMajor topic
Antineoplastic AgentsMajor topic
Protein Kinase InhibitorsMajor topic
Humans
Animals
Drug Resistance, Neoplasm
Tumor Microenvironment

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References90

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139,821,893It's all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma.J Neurooncol2025https://conductscience.org/library/papers/39821893PubMed
222,595,799Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet2012https://conductscience.org/library/papers/22595799PubMed
325,981,818
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol2015https://conductscience.org/library/papers/25981818PubMed
423,177,514Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet2013https://conductscience.org/library/papers/23177514PubMed
529,545,548Kinase inhibitors: the road ahead.Nat Rev Drug Discov2018https://conductscience.org/library/papers/29545548PubMed
633,854,043Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib.Cell Death Dis2021https://conductscience.org/library/papers/33854043PubMed
737,096,517[Effects of Decitabine Combined with Anlotinib on Proliferation and Apoptosis of Multiple Myeloma Cells].Zhongguo Shi Yan Xue Ye Xue Za Zhi2023https://conductscience.org/library/papers/37096517PubMed
819,692,680Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med2009https://conductscience.org/library/papers/19692680PubMed
916,014,882Erlotinib in previously treated non-small-cell lung cancer.N Engl J Med2005https://conductscience.org/library/papers/16014882PubMed
1029,151,359Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.N Engl J Med2018https://conductscience.org/library/papers/29151359PubMed

1 to 10 of 90

See all 90 references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42,740,781Primary sarcomatoid urothelial carcinoma of the ureter: A case report and literature review.Urol Case Rep2026https://conductscience.org/library/papers/42740781PubMed
42,433,250
Consolidation thoracic radiotherapy following quadruple induction with benmelstobart, anlotinib, and chemotherapy for extensive-stage small cell lung cancer: rationale and protocol of a phase II study.
Transl Lung Cancer Res2026https://conductscience.org/library/papers/42433250PubMed

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40944871

GET https://conductscience.org/api/papers/v1/40944871/references?page=2

API referenceFor AI assistants